Cholera

The Lancet

Volumn 390, Issue 10101, 2017, Pages 1539-1549

  Clemens, John D ^a,b,c   Nair, G Balakrish ^d   Ahmed, Tahmeed ^a   Qadri, Firdausi ^a   Holmgren, Jan ^e  

^a ICDDR B Centre for Health and Population Research   (Bangladesh)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Korea University College of Medicine   (South Korea)

^d WHO   (India)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLERA VACCINE; VIRULENCE FACTOR;

BACTERIAL VIRULENCE; BACTERIOLOGY; CASE FATALITY RATE; CHOLERA; EPIDEMIC; HOST SUSCEPTIBILITY; HUMAN; HYGIENE; INDONESIA; NONHUMAN; PANDEMIC; PATHOGENESIS; PRIORITY JOURNAL; REHYDRATION; REVIEW; SANITATION; SEROTYPE; VIBRIO CHOLERAE; WATER QUALITY; DIARRHEA; FLUID THERAPY; ISOLATION AND PURIFICATION; PATHOPHYSIOLOGY; PROCEDURES;

CHOLERA; DIARRHEA; DISEASE OUTBREAKS; FLUID THERAPY; HUMANS; INDONESIA; VIBRIO CHOLERAE;

EID: 85019704623     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)30559-7     Document Type: Review

References (147)

1. Joo, I, Barua, D, Burrows, W, (eds.) Cholera vaccines, 1974, Saunders, Cholera. Philadelphia, PA, 333–349.
2. Pollitzer, R, Cholera, 1959, World Health Organization, Geneva.
3. Harris, JB, LaRocque, RC, Qadri, F, Ryan, ET, Calderwood, SB, Cholera. Lancet 379 (2012), 2466–2476.
4. Van Heyningen, WE, Seal, JR, Cholera: The American scientific experience 1947–1980, 1983, Westview Press, Boulder, CO.
5. Snow, J, On the mode of communication of cholera, 1855, John Churchill, London.
6. Koch, R, Der zweite Bericht der deutschen cholera-commission. Dtsch Med Wochenschr, 9, 1883, 743.
7. Baine, WB, Mazzotti, M, Greco, D, et al. Epidemiology of cholera in Italy in 1973. Lancet 2 (1974), 1370–1374.
8. Cvjetanovic, B, Barua, D, The seventh pandemic of cholera. Nature 239 (1972), 137–138.
9. British Medical Journal. Cholera in Spain. Br Med J, 3, 1971, 266.
10. Goodgame, RW, Greenough, WB, Cholera in Africa: a message for the West. Ann Intern Med 82 (1975), 101–106.
11. Kustner, HG, Gibson, IH, Carmichael, TR, et al. The spread of cholera in South Africa. S Afr Med J 60 (1981), 87–90.
12. Swerdlow, DL, Mintz, ED, Rodriguez, M, et al. Waterborne transmission of epidemic cholera in Trujillo, Peru: lessons for a continent at risk. Lancet 340 (1992), 28–33.
13. Tanamal, ST, Notes on paracholera in Sulawesi (Celebes). Am J Trop Med Hyg 8 (1959), 72–78.
14. Weil, O, Berche, P, The cholera epidemic in Ecuador: towards an endemic in Latin America. Rev Epidemiol Sante Publique 40 (1992), 145–155.
15. Ali, M, Nelson, AR, Lopez, AL, Sack, DA, Updated global burden of cholera in endemic countries. PLoS Negl Trop Dis, 9, 2015, e0003832.
16. Colwell, RR, Global climate and infectious disease: the cholera paradigm. Science 274 (1996), 2025–2031.
17. Kirn, TJ, Jude, BA, Taylor, RK, A colonization factor links Vibrio cholerae environmental survival and human infection. Nature 438 (2005), 863–866.
18. Morris, JG Jr, Cholera and other types of vibriosis: a story of human pandemics and oysters on the half shell. Clin Infect Dis 37 (2003), 272–280.
19. Sack, DA, Sack, RB, Nair, GB, Siddique, AK, Cholera. Lancet 363 (2004), 223–233.
20. Meibom, KL, Blokesch, M, Dolganov, NA, Wu, CY, Schoolnik, GK, Chitin induces natural competence in Vibrio cholerae. Science 310 (2005), 1824–1827.
21. Waldor, MK, Mekalanos, JJ, Lysogenic conversion by a filamentous phage encoding cholera toxin. Science 272 (1996), 1910–1914.
22. Devault, AM, Golding, GB, Waglechner, N, et al. Second-pandemic strain of Vibrio cholerae from the Philadelphia cholera outbreak of 1849. N Engl J Med 370 (2014), 334–340.
23. Cholera Working Group. Large epidemic of cholera-like disease in Bangladesh caused by Vibrio cholerae O139 synonym Bengal. Lancet 342 (1993), 387–390.
24. Johnson, JA, Salles, CA, Panigrahi, P, et al. Vibrio cholerae O139 synonym bengal is closely related to Vibrio cholerae El Tor but has important differences. Infect Immun 62 (1994), 2108–2110.
25. Cameron, DN, Khambaty, FM, Wachsmuth, IK, Tauxe, RV, Barrett, TJ, Molecular characterization of Vibrio cholerae O1 strains by pulsed-field gel electrophoresis. J Clin Microbiol 32 (1994), 1685–1690.
26. Safa, A, Sultana, J, Dac Cam, P, Mwansa, JC, Kong, RY, Vibrio cholerae O1 hybrid El Tor strains, Asia and Africa. Emerg Infect Dis 14 (2008), 987–988.
27. Chin, CS, Sorenson, J, Harris, JB, et al. The origin of the Haitian cholera outbreak strain. N Engl J Med 364 (2011), 33–42.
28. Siddique, AK, Nair, GB, Alam, M, et al. El Tor cholera with severe disease: a new threat to Asia and beyond. Epidemiol Infect 138 (2010), 347–352.
29. World Health Organization. Cholera vaccines: WHO position paper. Wkly Epidemiol Rec 85 (2010), 117–128.
30. Clemens, J, Sack, D, Rao, M, et al. The design and analysis of cholera vaccine trials: recent lessons from Bangladesh. Int J Epidemiol 22 (1993), 724–730.
31. Hornick, RB, Music, SI, Wenzel, R, et al. The Broad Street pump revisited: response of volunteers to ingested cholera vibrios. Bull N Y Acad Med 47 (1971), 1181–1191.
32. Glass, RI, Lee, JV, Huq, MI, Hossain, KM, Khan, MR, Phage types of Vibrio cholerae O1 biotype El Tor isolated from patients and family contacts in Bangladesh: epidemiologic implications. J Infect Dis 148 (1983), 998–1004.
33. Faruque, SM, Biswas, K, Udden, SM, et al. Transmissibility of cholera: in vivo-formed biofilms and their relationship to infectivity and persistence in the environment. Proc Natl Acad Sci USA 103 (2006), 6350–6355.
34. Nelson, EJ, Chowdhury, A, Harris, JB, et al. Complexity of rice-water stool from patients with Vibrio cholerae plays a role in the transmission of infectious diarrhea. Proc Natl Acad Sci USA 104 (2007), 19091–19096.
35. Weil, AA, Begum, Y, Chowdhury, F, et al. Bacterial shedding in household contacts of cholera patients in Dhaka, Bangladesh. Am J Trop Med Hyg 91 (2014), 738–742.
36. Hartley, DM, Morris, JG Jr., Smith, DL., Hyperinfectivity: a critical element in the ability of V. cholerae to cause epidemics?. PLoS Med, 3, 2006, e7.
37. Jutla, AS, Akanda, AS, Griffiths, JK, Colwell, R, Islam, S, Warming oceans, phytoplankton, and river discharge: implications for cholera outbreaks. Am J Trop Med Hyg 85 (2011), 303–308.
38. Koelle, K, Rodo, X, Pascual, M, Yunus, M, Mostafa, G, Refractory periods and climate forcing in cholera dynamics. Nature 436 (2005), 696–700.
39. Pascual, M, Rodo, X, Ellner, SP, Colwell, R, Bouma, MJ, Cholera dynamics and El Nino-Southern Oscillation. Science 289 (2000), 1766–1769.
40. Faruque, SM, Role of phages in the epidemiology of cholera. Curr Top Microbiol Immunol 379 (2014), 165–180.
41. Mutreja, A, Kim, DW, Thomson, NR, et al. Evidence for multiple waves of global transmission within the seventh cholera pandemic. Nature 477 (2011), 462–465.
42. Waldor, MK, Tschape, H, Mekalanos, JJ, A new type of conjugative transposon encodes resistance to sulfamethoxazole, trimethoprim, and streptomycin in Vibrio cholerae O139. J Bacteriol 178 (1996), 4157–4165.
43. Clemens, J, Shin, S, Sur, D, Nair, GB, Holmgren, J, New-generation vaccines against cholera. Nat Rev Gastroenterol Hepatol 8 (2011), 701–710.
44. Banwell, JG, Pierce, NF, Mitra, RC, et al. Intestinal fluid and electrolyte transport in human cholera. J Clin Invest 49 (1970), 183–195.
45. Carpenter, CC, Sack, RB, Feeley, JC, Steenberg, RW, Site and characteristics of electrolyte loss and effect of intraluminal glucose in experimental canine cholera. J Clin Invest 47 (1968), 1210–1220.
46. De, SN, Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae. Nature 183 (1959), 1533–1534.
47. Lonnroth, I, Holmgren, J, Subunit structure of cholera toxin. J Gen Microbiol 76 (1973), 417–427.
48. Holmgren, J, Lonnroth, I, Svennerholm, L, Tissue receptor for cholera exotoxin: postulated structure from studies with GM1 ganglioside and related glycolipids. Infect Immun 8 (1973), 208–214.
49. Field, M, Fromm, D, al-Awqati, Q, Greenough, WB 3rd, Effect of cholera enterotoxin on ion transport across isolated ileal mucosa. J Clin Invest 51 (1972), 796–804.
50. Gill, DM, Meren, R, ADP-ribosylation of membrane proteins catalyzed by cholera toxin: basis of the activation of adenylate cyclase. Proc Natl Acad Sci USA 75 (1978), 3050–3054.
51. Holmgren, J, Actions of cholera toxin and the prevention and treatment of cholera. Nature 292 (1981), 413–417.
52. Ouchterlony, O, Holmgren, J, Cholera and related diarrheas: molecular aspects of a global health problem; 43rd Nobel Symposium, Stockholm, August 6–11, 1978, 1978, Karger, Stockholm.
53. Hardy, SJ, Holmgren, J, Johansson, S, Sanchez, J, Hirst, TR, Coordinated assembly of multisubunit proteins: oligomerization of bacterial enterotoxins in vivo and in vitro. Proc Natl Acad Sci USA 85 (1988), 7109–7113.
54. Wernick, NL, Chinnapen, DJ, Cho, JA, Lencer, WI, Cholera toxin: an intracellular journey into the cytosol by way of the endoplasmic reticulum. Toxins 2 (2010), 310–325.
55. Tsai, B, Rapoport, TA, Unfolded cholera toxin is transferred to the ER membrane and released from protein disulfide isomerase upon oxidation by Ero1. J Cell Biol 159 (2002), 207–216.
56. Gabriel, SE, Brigman, KN, Koller, BH, Boucher, RC, Stutts, MJ, Cystic fibrosis heterozygote resistance to cholera toxin in the cystic fibrosis mouse model. Science 266 (1994), 107–109.
57. Lundgren, O, Enteric nerves and diarrhoea. Pharmacol Toxicol 90 (2002), 109–120.
58. Herrington, DA, Hall, RH, Losonsky, G, Mekalanos, JJ, Taylor, RK, Levine, MM, Toxin, toxin-coregulated pili, and the toxR regulon are essential for Vibrio cholerae pathogenesis in humans. J Exp Med 168 (1988), 1487–1492.
59. Taylor, RK, Miller, VL, Furlong, DB, Mekalanos, JJ, Use of phoA gene fusions to identify a pilus colonization factor coordinately regulated with cholera toxin. Proc Natl Acad Sci USA 84 (1987), 2833–2837.
60. Silva, AJ, Leitch, GJ, Camilli, A, Benitez, JA, Contribution of hemagglutinin/protease and motility to the pathogenesis of El Tor biotype cholera. Infect Immun 74 (2006), 2072–2079.
61. Butler, SM, Camilli, A, Going against the grain: chemotaxis and infection in Vibrio cholerae. Nat Rev Microbiol 3 (2005), 611–620.
62. Sanchez, J, Holmgren, J, Cholera toxin structure, gene regulation and pathophysiological and immunological aspects. Cell Mol Life Sci 65 (2008), b1347–b1360.
63. Rothenbacher, FP, Zhu, J, Efficient responses to host and bacterial signals during Vibrio cholerae colonization. Gut Microbes 5 (2014), 120–128.
64. Evans, CA, Gilman, RH, Rabbani, GH, Salazar, G, Ali, A, Gastric acid secretion and enteric infection in Bangladesh. Trans R Soc Trop Med Hyg 91 (1997), 681–685.
65. Harris, JB, Khan, AI, LaRocque, RC, et al. Blood group, immunity, and risk of infection with Vibrio cholerae in an area of endemicity. Infect Immun 73 (2005), 7422–7427.
66. Glass, RI, Holmgren, J, Haley, CE, et al. Predisposition for cholera of individuals with O blood group. Possible evolutionary significance. Am J Epidemiol 121 (1985), 791–796.
67. Clemens, JD, Sack, DA, Harris, JR, et al. ABO blood groups and cholera: new observations on specificity of risk and modification of vaccine efficacy. J Infect Dis 159 (1989), 770–773.
68. Flach, CF, Qadri, F, Bhuiyan, TR, et al. Broad up-regulation of innate defense factors during acute cholera. Infect Immun 75 (2007), 2343–2350.
69. Larocque, RC, Sabeti, P, Duggal, P, et al. A variant in long palate, lung and nasal epithelium clone 1 is associated with cholera in a Bangladeshi population. Genes Immun 10 (2009), 267–272.
70. Karlsson, EK, Harris, JB, Tabrizi, S, et al. Natural selection in a Bangladeshi population from the cholera-endemic ganges river delta. Sci Transl Med 5 (2013), 192–286.
71. Clemens, JD, Sack, DA, Harris, JR, et al. Breast feeding and the risk of severe cholera in rural Bangladeshi children. Am J Epidemiol 131 (1990), 400–411.
72. Harris, JB, LaRocque, RC, Chowdhury, F, et al. Susceptibility to Vibrio cholerae infection in a cohort of household contacts of patients with cholera in Bangladesh. PLoS Negl Trop Dis, 2, 2008, e221.
73. Hsiao, A, Ahmed, AM, Subramanian, S, et al. Members of the human gut microbiota involved in recovery from Vibrio cholerae infection. Nature 515 (2014), 423–426.
74. von Seidlein, L, Wang, XY, Macuamule, A, et al. Is HIV infection associated with an increased risk for cholera? Findings from a case-control study in Mozambique. Trop Med Int Health 13 (2008), 683–688.
75. Ali, M, Emch, M, Park, JK, Yunus, M, Clemens, J, Natural cholera infection-derived immunity in an endemic setting. J Infect Dis 204 (2011), 912–918.
76. Bhuiyan, TR, Hoq, MR, Nishat, NS, et al. Enumeration of gut-homing β7-positive, pathogen-specific antibody-secreting cells in whole blood from enterotoxigenic Escherichia coli- and Vibrio cholerae-infected patients, determined using an enzyme-linked immunosorbent spot assay technique. Clin Vaccine Immunol 23 (2015), 27–36.
77. Bhuiyan, TR, Lundin, SB, Khan, AI, et al. Cholera caused by Vibrio cholerae O1 induces T-cell responses in the circulation. Infect Immun 77 (2009), 1888–1893.
78. Glass, RI, Svennerholm, AM, Khan, MR, Huda, S, Huq, MI, Holmgren, J, Seroepidemiological studies of El Tor cholera in Bangladesh: association of serum antibody levels with protection. J Infect Dis 151 (1985), 236–242.
79. Leung, DT, Rahman, MA, Mohasin, M, et al. Comparison of memory B cell, antibody-secreting cell, and plasma antibody responses in young children, older children, and adults with infection caused by Vibrio cholerae O1 El Tor Ogawa in Bangladesh. Clin Vaccine Immunol 18 (2011), 1317–1325.
80. Svennerholm, AM, Jertborn, M, Gothefors, L, Karim, AM, Sack, DA, Holmgren, J, Mucosal antitoxic and antibacterial immunity after cholera disease and after immunization with a combined B subunit-whole cell vaccine. J Infect Dis 149 (1984), 884–893.
81. Uddin, T, Harris, JB, Bhuiyan, TR, et al. Mucosal immunologic responses in cholera patients in Bangladesh. Clin Vaccine Immunol 18 (2011), 506–512.
82. Clemens, JD, van Loon, F, Sack, DA, et al. Field trial of oral cholera vaccines in Bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J Infect Dis 163 (1991), 1235–1242.
83. Holmgren, J, Svennerholm, AM, Cholera and the immune response. Prog Allergy 33 (1983), 106–119.
84. Leung, DT, Chowdhury, F, Calderwood, SB, Qadri, F, Ryan, ET, Immune responses to cholera in children. Expert Rev Anti Infect Ther 10 (2012), 435–444.
85. Jonson, G, Osek, J, Svennerholm, AM, Holmgren, J, Immune mechanisms and protective antigens of Vibrio cholerae serogroup O139 as a basis for vaccine development. Infect Immun 64 (1996), 3778–3785.
86. Clemens, JD, Sack, DA, Harris, JR, et al. Field trial of oral cholera vaccines in Bangladesh. Lancet 2 (1986), 124–127.
87. Glass, RI, Svennerholm, AM, Stoll, BJ, et al. Protection against cholera in breast-fed children by antibodies in breast milk. N Engl J Med 308 (1983), 1389–1392.
88. Lange, S, Holmgren, J, Protective antitoxic cholera immunity in mice: influence of route and number of immunizations and mode of action of protective antibodies. Acta Pathol Microbiol Scand C 86c (1978), 145–152.
89. Centers for Disease Control and Prevention. Laboratory identification of Vibrio cholerae. http://www.cdc.gov/cholera/pdf/laboratory-methods-for-the-diagnosis-of-vibrio-cholerae-chapter-6.pdf, 2016 (accessed Sept 11, 2016).
90. Telesmanich, NR, Lomov, Iu M, Laboratory diagnosis of cholera: analysis and prospects for improvement. Klin Lab Diagn 11 (2009), 51–55 (in Russian).
91. Benenson, AS, Islam, MR, Greenough, WB 3rd, Rapid identification of Vibrio cholerae by darkfield microscopy. Bull World Health Organ 30 (1964), 827–831.
92. Bhuiyan, NA, Qadri, F, Faruque, AS, et al. Use of dipsticks for rapid diagnosis of cholera caused by Vibrio cholerae O1 and O139 from rectal swabs. J Clin Microbiol 41 (2003), 3939–3941.
93. George, CM, Rashid, MU, Sack, DA, et al. Evaluation of enrichment method for the detection of Vibrio cholerae O1 using a rapid dipstick test in Bangladesh. Trop Med Int Health 19 (2014), 301–307.
94. Qadri, F, Hasan, JA, Hossain, J, et al. Evaluation of the monoclonal antibody-based kit Bengal SMART for rapid detection of Vibrio cholerae O139 synonym Bengal in stool samples. J Clin Microbiol 33 (1995), 732–734.
95. Rahman, M, Sack, DA, Mahmood, S, Hossain, A, Rapid diagnosis of cholera by coagglutination test using 4-h fecal enrichment cultures. J Clin Microbiol 25 (1987), 2204–2206.
96. Ramamurthy, T, Nair, G, Quilici, M, Cholera surveillance, rapid diagnostics and laboratory networks. Wkly Epidemiol Rec 90 (2015), 537–539.
97. Hoshino, K, Yamasaki, S, Mukhopadhyay, AK, et al. Development and evaluation of a multiplex PCR assay for rapid detection of toxigenic Vibrio cholerae O1 and O139. FEMS Immunol Med Microbiol 20 (1998), 201–207.
98. Huang, J, Zhu, Y, Wen, H, et al. Quadruplex real-time PCR assay for detection and identification of Vibrio cholerae O1 and O139 strains and determination of their toxigenic potential. Appl Environ Microbiol 75 (2009), 6981–6985.
99. Liu, J, Gratz, J, Amour, C, et al. A laboratory-developed TaqMan Array Card for simultaneous detection of 19 enteropathogens. J Clin Microbiol 51 (2013), 472–480.
100. Lindenbaum, J, Greenough, WB, Islam, MR, Antibiotic therapy of cholera in children. Bull World Health Organ 37 (1967), 529–538.
101. Clemens, J, Shin, S, Shah, B, Sack, D, Cholera vaccines. In: Plotkin S, Orenstein W, Offit P, eds. Vaccines, 5th ed, 2013, Elsevier, Amsterdam.
102. Tariq, M, Memon, M, Jafferani, A, et al. Massive fluid requirements and an unusual BUN/creatinine ratio for pre-renal failure in patients with cholera. PLoS One, 4, 2009, e7552.
103. Bennish, ML, Azad, AK, Rahman, O, Phillips, RE, Hypoglycemia during diarrhea in childhood. Prevalence, pathophysiology, and outcome. N Engl J Med 322 (1990), 1357–1363.
104. Ciglenecki, I, Bichet, M, Tena, J, et al. Cholera in pregnancy: outcomes from a specialized cholera treatment unit for pregnant women in Leogane, Haiti. PLoS Negl Trop Dis, 7, 2013, e2368.
105. Alam, NH, Ashraf, H, Treatment of infectious diarrhea in children. Paediatr Drugs 5 (2003), 151–165.
106. WHO. Pocket book of hospital care for children: guidelines for the management of common childhood illnesses, 2nd edn, 2013, World Health Organization, Geneva.
107. WHO. The treatment of diarrhoea: a manual for physicians and other senior health workers (4th revision), 2005, World Health Organization, Geneva.
108. Ramakrishna, BS, Venkataraman, S, Srinivasan, P, Dash, P, Young, GP, Binder, HJ, Amylase-resistant starch plus oral rehydration solution for cholera. N Engl J Med 342 (2000), 308–313.
109. Ahmed, T, Ali, M, Ullah, MM, et al. Mortality in severely malnourished children with diarrhoea and use of a standardised management protocol. Lancet 353 (1999), 1919–1922.
110. WHO Multicentre Growth Reference Study Group. WHO child growth standards based on length/height, weight and age. Acta Paediatr Suppl 450 (2006), 76–85.
111. WHO. Guideline: updates on the management of severe acute malnutrition in infants and children, 2013, World Health Organization, Geneva.
112. Alam, NH, Hamadani, JD, Dewan, N, Fuchs, GJ, Efficacy and safety of a modified oral rehydration solution (ReSoMaL) in the treatment of severely malnourished children with watery diarrhea. J Pediatr 143 (2003), 614–619.
113. Greenough, WB 3rd, Gordon, RS Jr, Rosenberg, IS, Davies, BI, Benenson, AS, Tetracycline in the treatment of cholera. Lancet 1 (1964), 355–357.
114. Kaushik, JS, Gupta, P, Faridi, MM, Das, S, Single dose azithromycin versus ciprofloxacin for cholera in children: a randomized controlled trial. Indian Pediatr 47 (2010), 309–315.
115. Saha, D, Karim, MM, Khan, WA, Ahmed, S, Salam, MA, Bennish, ML, Single-dose azithromycin for the treatment of cholera in adults. N Engl J Med 354 (2006), 2452–2462.
116. Roy, SK, Hossain, MJ, Khatun, W, et al. Zinc supplementation in children with cholera in Bangladesh: randomised controlled trial. BMJ 336 (2008), 266–268.
117. WHO. Clinical management of acute diarrhoea. WHO/FCH/CAH/04.7, 2004, World Health Organization/Unicef joint statement, Geneva.
118. Cutler, D, Miller, G, The role of public health improvements in health advances: the twentieth-century United States. Demography 42 (2005), 1–22.
119. WHO Unicef. Progress on sanitation and drinking water: 2015 update and MDG assessment, 2015, World Health Organization, Unicef, Geneva.
120. Colwell, RR, Huq, A, Islam, MS, et al. Reduction of cholera in Bangladeshi villages by simple filtration. Proc Natl Acad Sci USA 100 (2003), 1051–1055.
121. Deb, BC, Sircar, BK, Sengupta, PG, et al. Studies on interventions to prevent El Tor cholera transmission in urban slums. Bull World Health Organ 64 (1986), 127–131.
122. O'Connor, KA, Cartwright, E, Loharikar, A, et al. Risk factors early in the 2010 cholera epidemic, Haiti. Emerg Infect Dis 17 (2011), 2136–2138.
123. George, CM, Monira, S, Sack, DA, et al. Randomized controlled trial of hospital-based hygiene and water treatment intervention (CHoBI7) to reduce cholera. Emerg Infect Dis 22 (2016), 233–241.
124. Benenson, AS, Joseph, PR, Oseasohn, RO, Cholera vaccine field trials in east Pakistan. 1. Reaction and antigenicity studies. Bull World Health Organ 38 (1968), 347–357.
125. Cash, RA, Music, SI, Libonati, JP, Craig, JP, Pierce, NF, Hornick, RB, Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis 130 (1974), 325–333.
126. Cohen, MB, Giannella, RA, Bean, J, et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun 70 (2002), 1965–1970.
127. Coster, TS, Killeen, KP, Waldor, MK, et al. Safety, immunogenicity, and efficacy of live attenuated Vibrio cholerae O139 vaccine prototype. Lancet 345 (1995), 949–952.
128. Garcia, L, Jidy, MD, Garcia, H, et al. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 73 (2005), 3018–3024.
129. Levine, MM, Kaper, JB, Herrington, D, et al. Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet 2 (1988), 467–470.
130. Liang, W, Wang, S, Yu, F, et al. Construction and evaluation of a safe, live, oral Vibrio cholerae vaccine candidate, IEM108. Infect Immun 71 (2003), 5498–5504.
131. Mahalanabis, D, Ramamurthy, T, Nair, GB, et al. Randomized placebo controlled human volunteer trial of a live oral cholera vaccine VA1.3 for safety and immune response. Vaccine 27 (2009), 4850–4856.
132. Tacket, CO, Losonsky, G, Nataro, JP, et al. Initial clinical studies of CVD 112 Vibrio cholerae O139 live oral vaccine: safety and efficacy against experimental challenge. J Infect Dis 172 (1995), 883–886.
133. Richie, EE, Punjabi, NH, Sidharta, YY, et al. Efficacy trial of single-dose live oral cholera vaccine CVD 103-HgR in North Jakarta, Indonesia, a cholera-endemic area. Vaccine 18 (2000), 2399–2410.
134. Chen, WH, Cohen, MB, Kirkpatrick, BD, et al. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with Vibrio cholerae O1 El Tor. Clin Infect Dis 62 (2016), 1329–1335.
135. Lewis, DJ, Gilks, CF, Ojoo, S, et al. Immune response following oral administration of cholera toxin B subunit to HIV-1-infected UK and Kenyan subjects. AIDS 8 (1994), 779–785.
136. Bhattacharya, SK, Sur, D, Ali, M, et al. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial. Lancet Infect Dis 13 (2013), 1050–1056.
137. Qadri, F, Wierzba, TF, Ali, M, et al. Efficacy of a single-dose, inactivated oral cholera vaccine in Bangladesh. N Engl J Med 374 (2016), 1723–1732.
138. WHO. Potential use of oral cholera vaccines in emergency situations: report of a WHO meeting. http://apps.who.int/iris/bitstream/10665/66004/1/WHO_CDS_CSR_EDC_99.4.pdf, 1999 Geneva, Switzerland 12–13 May (accessed Feb 20, 2017).
139. WHO. Cholera, 2014. Wkly Epidemiol Rec 90 (2015), 517–544.
140. Harris, JB, Larocque, RC, Charles, RC, Mazumder, RN, Khan, AI, Bardhan, PK, Cholera's western front. Lancet 376 (2010), 1961–2055.
141. Ali, M, Emch, M, von Seidlein, L, et al. Herd immunity conferred by killed oral cholera vaccines in Bangladesh: a reanalysis. Lancet 366 (2005), 44–49.
142. Longini, IM Jr., Nizam, A., Ali, M., Yunus, M., Shenvi, N., Clemens, JD., Controlling endemic cholera with oral vaccines. PLoS Med, 4, 2007, e336.
143. WHO. WHO Technical Working Group on creation of an oral cholera vaccine stockpile: meeting report, Geneva, 26–27 April. http://apps.who.int/iris/bitstream/10665/75240/1/WHO_HSE_PED_2012_2_eng.pdf, 2012 (accessed Feb 20, 2017).
144. Luquero, FJ, Grout, L, Ciglenecki, I, et al. Use of Vibrio cholerae vaccine in an outbreak in Guinea. N Engl J Med 370 (2014), 2111–2120.
145. Martin, S, Lopez, AL, Bellos, A, et al. Post-licensure deployment of oral cholera vaccines: a systematic review. Bull World Health Organ 92 (2014), 881–893.
146. Qadri, F, Ali, M, Chowdhury, F, et al. Feasibility and effectiveness of oral cholera vaccine in an urban endemic setting in Bangladesh: a cluster randomised open-label trial. Lancet 386 (2015), 1362–1371.
147. Clemens, J, Holmgren, J, When, how, and where can oral cholera vaccines be used to interrupt cholera outbreaks?. Curr Top Microbiol Immunol 379 (2014), 231–258.